Actively Recruiting

Age: 18Years +
All Genders
ID07175077

7T Brain MRI Scan for Micro-brain Metastasis Detection in Patients With Small-cell Lung Cancer Who Decline Prophylactic Cranial Irradiation

Led by University of Missouri-Columbia · Updated on 2025-12-02

20

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University of Missouri-Columbia

Lead Sponsor

S

Siemens Medical Solutions

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying patients diagnosed with small-cell lung cancer (SCLC) who have declined prophylactic cranial irradiation (PCI). The study compares the use of a 7-tesla (7t) brain MRI scan to standard care 1.5t or 3t MRI scans to determine if the 7t MRI can detect brain metastases earlier than current methods. Patients must have had a recent standard MRI that showed no brain metastases to participate. Participants will first undergo a 7t MRI brain scan, followed by up to 12 months of standard care MRI scans (either 1.5t or 3t). The study will monitor patients regularly through these scans to observe if and when brain metastases develop. Once brain metastases are confirmed by standard scans, the results will be compared to the earlier 7t MRI images to evaluate the potential for earlier detection. Throughout the study, participants will be followed for up to one year or until brain metastases are detected. The primary outcome is the detection of brain metastases using the 7t MRI at 3, 6, 9, and 12 months after the initial 7t scan. Patients will continue their regular clinical care and surveillance with brain MRI scans. The study involves no treatment changes but focuses on imaging assessment and monitoring.

CONDITIONS

Brief Title

7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient must have a confirmed diagnosis of small-cell lung cancer (SCLC).
  • Patient must have had a brain MRI (1.5t or 3t) within 4 weeks prior to consent showing no brain metastases or leptomeningeal disease.
  • Patient must have no history of brain metastases or leptomeningeal disease.
  • Patient must have declined prophylactic cranial irradiation (PCI) and agree to surveillance with brain MRI scans.
  • Patient must be 18 years of age or older.
  • Patient must have an ECOG Performance Status of 0 to 2.
  • Patient must be able to tolerate the 7T MRI scan.
Not Eligible

You will not qualify if you...

  • Patient must not have any contraindications to MRI, such as implanted metal devices or foreign bodies.
  • Patient must not have contraindications to gadolinium contrast used during MRI.
  • Patient must not have other metastatic cancers requiring active treatment.
  • Pregnant patients are excluded; pregnancy status will be confirmed verbally.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for confirming eligibility including review of recent MRI results

Implementation

Duration - 1 day

Participants undergo a 7T brain MRI scan to detect micro-brain metastases.

1 visit (in-person) for the 7T MRI scan

Long-term Monitoring

Duration - Up to 12 months

Participants are followed with standard of care brain MRI scans for up to 12 months or until brain metastases are detected.

Brain MRI scans at approximately 3, 6, 9, and 12 months after the 7T MRI scan

Trial Site Locations

Total: 1 location

1

University of Missouri

Columbia, Missouri, United States, 65212

Actively Recruiting

Loading map...

Research Team

B

Brooke McDaniel

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastas...

Brain Metastases

Actively Recruiting

1 location

Predicting Immunotherapy Efficacy from Analysis of Pre-treat...

Cancer of Head and Neck

Actively Recruiting

1 location

A Phase II Study of Nivolumab With Ipilimumab and Cabozantin...

Brain Metastases

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here